Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): A retrospective population-based study in a Canadian population.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
02
2018
accepted:
12
01
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
23
11
2019
Statut:
epublish
Résumé
We aimed to describe medication use in pregnancies that resulted in births and abortions, as well as use after a pregnancy-related visit to characterize the receipt of medication after knowledge of pregnancy. Abortions included both spontaneous and induced abortions. Rates of medication use among women with a pregnancy outcome (2001-2013) were described using the Manitoba Population Research Data Repository at the Manitoba Centre for Health Policy. Use was determined as ≥ 1 prescription filled during pregnancies that resulted in births (livebirth/stillbirth) and abortions. Rates were calculated at any time during pregnancy and after a pregnancy-related visit. Rates were additionally characterized by risk in pregnancy using Briggs classification (2017). Of 174,848 birth pregnancies, overall 64.9% filled ≥ 1 prescription during pregnancy (a significant increase from 62.3% to 68.8% from 2001-2013, p<0.0001); 55.4% filled ≥ 1 prescription after a pregnancy-related visit. Of 71,967 abortions, 44.7% filled ≥ 1 prescription (a significant increase from 42.6% to 46.8% from 2001-2013, p<0.0001). Only 3.7% of birth pregnancies had at least one prescription for a contraindicated medication (according to Briggs classification), whereas 10.8% of abortions filled a prescription for a contraindicated medication. The most common drugs used in pregnancy were amoxicillin, doxylamine, codeine combinations, nitrofurantoin, cephalexin, salbutamol and ranitidine. Fewer women filled prescriptions for undesirable medications according to Briggs classification during pregnancy after a pregnancy-related visit.
Identifiants
pubmed: 30840711
doi: 10.1371/journal.pone.0211319
pii: PONE-D-18-06381
pmc: PMC6402756
doi:
Substances chimiques
Prescription Drugs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211319Subventions
Organisme : CIHR
Pays : Canada
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Obstet Gynecol. 2011 Jul;205(1):51.e1-8
pubmed: 21514558
Am J Obstet Gynecol. 2003 Apr;188(4):1039-45
pubmed: 12712107
Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):895-902
pubmed: 21774029
BMJ Open. 2014 Nov 12;4(11):e005602
pubmed: 25392022
Clin Epidemiol. 2011 Feb 01;3:43-50
pubmed: 21386973
Nurs Womens Health. 2015 Jun-Jul;19(3):266-70
pubmed: 26058910
Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):537-45
pubmed: 16700083
Br J Clin Pharmacol. 2008 May;65(5):653-60
pubmed: 18294334
Epidemiology. 2012 Sep;23(5):699-705
pubmed: 22766750
Am J Obstet Gynecol. 2004 Aug;191(2):398-407
pubmed: 15343213
PLoS One. 2015 May 26;10(5):e0128312
pubmed: 26011706
Fed Regist. 2014 Dec 4;79(233):72063-103
pubmed: 25509060
Can Fam Physician. 2010 Mar;56(3):239-41
pubmed: 20228306
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):335-42
pubmed: 25627986
PLoS One. 2014 Apr 04;9(4):e93870
pubmed: 24705674
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1013-8
pubmed: 23893932
Obstet Gynecol. 2018 May;131(5):789-798
pubmed: 29630018
Clin Epidemiol. 2011;3:149-56
pubmed: 21607016
Lancet. 2000 Nov 18;356(9243):1735-6
pubmed: 11095263
Clin Ther. 2012 Jan;34(1):239-249.e2
pubmed: 22169049
J Clin Epidemiol. 1999 Jan;52(1):39-47
pubmed: 9973072
Pharmacoepidemiol Drug Saf. 2009 Mar;18(3):211-25
pubmed: 19173342
Obstet Gynecol. 2015 Sep;126(3):465-73
pubmed: 26244530
Med Care. 1982 Mar;20(3):266-76
pubmed: 7078285
Eur J Clin Pharmacol. 2008 Nov;64(11):1125-32
pubmed: 18685836